Pfizer Wins $10bn Fight for Metsera, Gaining Foothold in Obesity Drug Market

Pfizer has clinched a $10 billion deal to acquire Metsera, the U.S. biotech developer of experimental obesity drugs, marking the end of a heated bidding war with Novo Nordisk that captivated the pharmaceutical industry. The acquisition gives Pfizer a much-needed entry into the booming obesity drug market, which analysts project could reach $150 billion by

Read More